J J Irlam-Jones

  • Citations Per Year
Learn More
Background:The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts benefit from hypoxia modification.Methods:In all, 183 T1–T4a(More)
  • 1